Innovating Works

TROJANANOHORSE

Financiado
Hybrid immune eluding nanocrystals as smart and active theranostic weapons again...
Nanomedicine tools for cancer treatment comprise many nanosized systems, so far developed with smart functions such as efficient drug delivery and cell targeting abilities. However they remain still undercharacterized in terms of... Nanomedicine tools for cancer treatment comprise many nanosized systems, so far developed with smart functions such as efficient drug delivery and cell targeting abilities. However they remain still undercharacterized in terms of immunogenicity, potential toxicity due to the materials itself or the unwanted release of drugs. To overcome these challenges this project aims to develop a new generation of multifunctional therapeutic and diagnostic (thus theranostics) nanosystems displaying non-immunogenicity, improved cancer treatment, cell imaging, and high safety for the hosting organism. The innovative concept behind this approach relies on a core-shell nanosystem with a therapeutically active core, i.e. a TrojaNanoHorse (TNH), here validated against leukaemia. The injectable TNH have a lipid bilayer shell derived from autologous cancer cell membrane, naturally non-immunogenic. The hemocompatibility, antithrombogenicity, and targeting ability with antibodies toward malignant blood cells will be proved during this project. Studies will show the zinc oxide nanocrystal core activation developing toxic reactive oxygen species (ROS) for cancer killing, and its green fluorescence emission. The whole TNH would go beyond the state-of-the-art due to its nature-derived biomimetic shell, absence of drugs, its safety and biodegrading fate, and green luminescent emissions for diagnosis. This project will also develop novel set-up for non-immunogenic therapy and diagnosis, impacting on future technology, new standardized protocols for nanomaterial safety assessment, and study chemical and biological mechanism of ROS development effects on cancer cell. Achieving the ultimate goal of a multifunctional TNH will require multidisciplinary expertise in chemistry, material science, biology, medicine and engineering, opening new horizons as nanomedicine tools for efficient cancer therapy with strong scientific, technological and socio-economic benefits. ver más
31/08/2021
1M€
Duración del proyecto: 66 meses Fecha Inicio: 2016-02-22
Fecha Fin: 2021-08-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2021-08-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-StG-2015: ERC Starting Grant
Cerrada hace 9 años
Presupuesto El presupuesto total del proyecto asciende a 1M€
Líder del proyecto
POLITECNICO DI TORINO No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5